mRNA and Peptide Vaccines in Melanoma-Current Landscape and Future Direction.

Cells · 2026 · PMC12939437 · PMID 41744786

Europe PMC DOI

hedged sentence

0.0558

closest p · 1.1× alpha

0.0558

boldest claim

The sentences

narrowly missed statistical significancep = 0.0558so close (0.05 < p ≤ 0.1)

In the confirmatory Phase III study of upfront IDO/PD-L1 vaccine (IO102-IO103) in combination with pembrolizumab versus pembrolizumab alone in advanced melanoma, the primary endpoint of mPFS narrowly missed statistical significance (19.4 months vs. 11.0 months; HR 0.77; 95% CI 0.58–1.00; p = 0.0558).

also in 227 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.